Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

被引：0
|
作者：
Samalin, E. [1 ]
Bouche, O. [2 ]
Thezenas, S. [1 ]
Francois, E. [3 ]
Adenis, A. [4 ]
Bennouna, J. [5 ]
Taieb, J. [6 ]
Desseigne, F. [7 ]
Laurent-Puig, P. [6 ]
Ychou, M. [8 ]
机构：
[1] CRLC Val dAurelle, Stat, Montpellier 5, France
[2] CHU Robert Debre, Reims, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Oscar Lambret, F-59020 Lille, France
[5] Ctr Rene Gauducheau, F-44035 Nantes, France
[6] Hop Georges Pompidou, APHP, Paris 15, France
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CRLC Val dAurelle, Oncol, Montpellier 5, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71736-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [1] INTERIM ANALYSIS RESULTS OF MULTICENTRE PHASE II TRIAL ASSESSING SORAFENIB IN COMBINATION WITH IRINOTECAN AS 2ND OR LATER-LINE IN METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATION (NEXIRI)
    Samalin, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 67
  • [2] Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Seitz, J. F.
    Conroy, T.
    Galais, M. P.
    Assenat, E.
    Crapez, E.
    Poujol, S.
    Bibeau, F.
    Boissiere, F.
    Laurent-Puig, P.
    Ychou, M.
    Mazard, T.
    BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1148 - 1154
  • [3] Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
    E Samalin
    O Bouché
    S Thézenas
    E Francois
    A Adenis
    J Bennouna
    J Taieb
    F Desseigne
    J F Seitz
    T Conroy
    M P Galais
    E Assenat
    E Crapez
    S Poujol
    F Bibeau
    F Boissière
    P Laurent-Puig
    M Ychou
    T Mazard
    British Journal of Cancer, 2014, 110 : 1148 - 1154
  • [4] Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).
    Ychou, M.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Seitz, J.
    Conroy, T.
    Galais, M.
    Crapez, E.
    Poujol, S.
    Bibeau, F.
    Laurent-Puig, P.
    Samalin, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: Interim analysis results of multicenter phase II part trial (NEXIRI)
    Ychou, M.
    Francois, E.
    Thezenas, S.
    Laurent-Puig, P.
    Adenis, A.
    Bennouna, J.
    Assonat, E.
    Portales, F.
    Samalin, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2).
    Samalin, Emmanuelle
    De la Fouchardiere, Christelle
    Thezenas, Simon
    Boige, Valerie
    Senellart, Helene
    Guimbaud, Rosine
    Taieb, Julien
    Francois, Eric
    Galais, Marie-Pierre
    Adenis, Antoine
    Lievre, Astrid
    Seitz, Jean-Francois
    Metges, Jean-Philippe
    Bouche, Olivier
    Fonck, Marianne
    Di Fiore, Frederic
    Artru, Pascal
    Aparicio, Thomas
    Mazard, Thibault
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)
    Samalin, E.
    de la Fouchardiere, C.
    Thezenas, S.
    Boige, V.
    Senellart, H.
    Guimbaud, R.
    Taieb, J.
    Francois, E.
    Galais, M-P.
    Adenis, A.
    Lievre, A.
    Dahan, L.
    Di Fiore, F.
    Boissiere, F.
    Crapez, E.
    Bibeau, F.
    Ho-Pun-Cheung, A.
    Poujol, S.
    Mazard, T.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).
    Samalin, Emmanuelle
    De La Fouchardiere, Christelle
    Thezenas, Simon
    Boige, Valerie
    Senellart, Helene
    Guimbaud, Rosine
    Taieb, Julien
    Francois, Eric
    Galais, Marie -Pierre
    Adenis, Antoine
    Lievre, Astrid
    Seitz, Jean-Francois
    Metges, Jean-Philippe
    Di Fiore, Frederic
    Boissiere, Florence
    Lopez-Crapez, Evelyne
    Bibeau, Frederic
    Ho-Pun-Cheung, Alexandre
    Mazard, Thibault
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer (MCRC) patients
    Samalin, E.
    Lievre, A.
    Boyer-Gestin, C.
    Mitry, E.
    Senesse, P.
    Lepere, C.
    Bachet, J.
    Vaillant, J.
    Rougier, J.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2007, 18 : VII30 - VII30
  • [10] LONG TERM RESULTS OF A MULTICENTRE PHASE II TRIAL ASSESSING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS ACCORDING TO KRAS STATUS
    Samalin, E.
    Francoise, D.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 23 - 23
12345